Leukocyte reduction of blood components: public policy and new technology.

Dzik, S; Aubuchon, J; Jeffries, L; Kleinman, S; Manno, C; Murphy, M F; Popovsky, M A; Sayers, M; Silberstein, L E; Slichter, S J; Vamvakas, E C

Dzik, S; Aubuchon, J; Jeffries, L; Kleinman, S; Manno, C; Murphy, M F; Popovsky, M A; Sayers, M; Silberstein, L E; Slichter, S J; Vamvakas, E C.

Affiliation

Dzik S; Blood Transfusion Service, Massachusetts General Hospital, Boston 02114, USA.

Transfus Med Rev ; 14(1): 34-52, 2000 Jan.

Article in En | MEDLINE | ID: mdl-10669939

Subject(s)

Blood Component Removal/standards; Blood Component Transfusion/standards; Leukocytes/immunology; Adjuvants, Immunologic; Blood Component Removal/adverse effects; Blood Component Removal/economics; Blood Component Transfusion/adverse effects; Blood Component Transfusion/economics; Costs and Cost Analysis; Creutzfeldt-Jakob Syndrome/prevention & control; Europe; Humans; Immune System/physiopathology; Public Policy; United States

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Blood Component Removal / Blood Component Transfusion / Leukocytes Type of study: Health_economic_evaluation Limits: Humans Country/Region as subject: America do norte / Europa Language: En Journal: Transfus Med Rev Journal subject: HEMATOLOGIA Year: 2000 Document type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links